PBAC's latest decision on Lanthanum carbonate: Not recommended (2007). Considered for Treatment of hyperphosphataemia in adult patients with chronic renal failure on dialysis whose serum calcium levels are at least 2.60 mmol/L.
PBAC outcome
Not recommended
2007
ICER (AUD/QALY)
$75k/QALY
Range: $45k/QALY–$75k/QALY
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
adult patients with chronic renal failure on dialysis whose serum calcium levels are at least 2.60 mmol/L
Therapy area
Renal disease
Evidence base
RCT, Registry
Primary endpoint
PO controlled patients (PO ≤ 1.80mmol/L)
Key trials
LAM-IV-301, LAM-IV-303, LAM-IV-307
Comparator
calcium carbonate
Economic model
CUA, Cost-minimisation
Why PBAC said no
Reasons cited in the latest PSD: High and uncertain cost-effectiveness ratio, lack of data conclusively linking treatment effects to patient-relevant outcomes such as reduction in mortality, unproven equi-efficacy with calcium carbonate in reducing phosphate levels, trial population not representative of PBS target population, uncertainty about clinical significance of hypercalcaemic events, flawed trial design